Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
With the combination of oral solid, inhalation, dermatology, high potent and oral contraceptive products, this is an important facility of the company
The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK
Lutio has the potential to offer significant cost savings when available to UK patients.
The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements
A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
The clinical research organisation located in Hyderabad is a USFDA inspected facility
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Subscribe To Our Newsletter & Stay Updated
